U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H25ClN2O5.C7H6O2
Molecular Weight 530.997
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVAMLODIPINE BENZOATE

SMILES

OC(=O)C1=CC=CC=C1.CCOC(=O)C2=C(COCCN)NC(C)=C([C@@H]2C3=C(Cl)C=CC=C3)C(=O)OC

InChI

InChIKey=RVPCEXXEUXIPEO-LMOVPXPDSA-N
InChI=1S/C20H25ClN2O5.C7H6O2/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;8-7(9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,8,9)/t17-;/m0./s1

HIDE SMILES / InChI
Levalmodipine (S-amlodipine) is an active enantiomer of amlodipine, a calcium antagonist that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that S-amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. S-Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Enantiomerically pure S-amlodipine is marketed in some countries worldwide, while racemate, containing active S-enantiomer an inactive R-enantiomer is marketed in the USA and indicated for the treatment of hypertension and coronary artery disease.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.71 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TELMISARTAN
LEVAMLODIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.1 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMLODIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
147.43 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TELMISARTAN
LEVAMLODIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
161.7 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMLODIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
45.1 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TELMISARTAN
LEVAMLODIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
55 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVAMLODIPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
yes [IC50 40.12 uM]
yes [IC50 9.55 uM]
yes [Ki 21.45 uM]
yes [Ki 7.22 uM]
yes [Ki 8.95 uM]
Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
Name Type Language
LEVAMLODIPINE BENZOATE
Common Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 2-((2-AMINOETHOXY)METHYL)-4-(2-CHLOROPHENYL)-1,4-DIHYDRO-6-METHYL-, 3-ETHYL 5-METHYL ESTER, (4S)-, MONOBENZOATE
Systematic Name English
Code System Code Type Description
CAS
865361-13-3
Created by admin on Sat Dec 16 15:16:42 GMT 2023 , Edited by admin on Sat Dec 16 15:16:42 GMT 2023
PRIMARY
CAS
1391358-31-8
Created by admin on Sat Dec 16 15:16:42 GMT 2023 , Edited by admin on Sat Dec 16 15:16:42 GMT 2023
NON-SPECIFIC STOICHIOMETRY
PUBCHEM
46935363
Created by admin on Sat Dec 16 15:16:42 GMT 2023 , Edited by admin on Sat Dec 16 15:16:42 GMT 2023
PRIMARY
FDA UNII
9X6S45HU2Q
Created by admin on Sat Dec 16 15:16:42 GMT 2023 , Edited by admin on Sat Dec 16 15:16:42 GMT 2023
PRIMARY